Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer

Figure 1 Flowchart of database search and study inclusion. mCRC: Metastatic colorectal cancer; ICI: Immune checkpoint inhibitor; HR: Hazard ratio.

Figure 2 Forest plots for the meta-analysis of the association between liver metastasis and progression-free survival in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Overall meta-analysis; B: Subgroup analysis according to study design; C: Subgroup analysis according to the type of metastatic colorectal cancer. 95%CI: 95% confidence interval.

Figure 3 Forest plots for the subgroup analyses of the association between liver metastasis and progression-free survival in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Subgroup analysis according to mean age of the patients; B: Subgroup analysis according to follow-up duration; C: Subgroup analysis according to analytic model. 95%CI: 95% confidence interval.

Figure 4 Forest plots for the meta-analysis of the association between liver metastasis and overall survival in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Overall meta-analysis; B: Subgroup analysis according to study design; C: Subgroup analysis according to the type of metastatic colorectal cancer. 95%CI: 95% confidence interval.

Figure 5 Forest plots for the subgroup analyses of the association between liver metastasis and overall survival in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Subgroup analysis according to mean age of the patients; B: Subgroup analysis according to follow-up duration; C: Subgroup analysis according to analytic model. 95%CI: 95% confidence interval.

Figure 6 Funnel plots for estimating the potential publication biases underlying the meta-analyses of the association between liver metastasis and survival outcomes in patients with metastatic colorectal cancer treated with immune checkpoint inhibitors. A: Funnel plots for the meta-analysis of the association between liver metastasis and progression-free survival in patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs); B: Bunnel plots for the meta-analysis of the association between liver metastasis and overall survival in patients with mCRC treated with ICIs.